Leland Stanford Junior University

Johns Hopkins University

The United States Government As Represented by the Department of Veterans Affairs

Xinguo Jiang

Mark R Nicolls

Geoffrey C Gurtner

Jayakumar Rajadas

Gregg L Semenza

Gundeep Dhillon

Wen A Tian

Stanley G Rockson

Jeanna Kim

Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.

HIF-1 modulator paint formulation and uses thereof

Provided are therapeutic methods for treating a patient with lymphedema, or prophylactically treating an individual susceptible to lymphedema, by inhibiting synthesis activity of leukotriene B.

LTB4 inhibition to prevent and treat human lymphedema

Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection.

Iron chelators and use thereof for reducing transplant failure during rejection episodes

Growing community of inventors

Palo Alto, CA, United States of America

Xinguo Jiang